碳离子放疗(CIRT)治疗胰腺癌的HIT初步放疗计划分析:前瞻性II期PACK研究
分析海德堡离子治疗中心(HIT)前瞻性II期PACK研究中14例胰腺癌患者的碳离子放疗计划,比较LEM-I与NIRS-MKM两种生物模型计算的生物剂量及LETd分布,并基于NIRS经验推导新的胃肠道约束条件进行再优化。结果显示HIT现行标准与日本经验高度一致,但为改善肿瘤覆盖可考虑放宽胃肠道约束。
要点
- 14例胰腺癌患者计划再计算显示仅2例GTV的LETd98%大于44 keV/μm。
- 基于NIRS经验推导的HIT胃肠道剂量约束替代了HIT标准Dmax=45.6 GyRBEHIT。
- 与原始DBio|HIT相比,DBio|NIRS-const_48Gy和DBio|NIRS-const_50.4Gy使ITV的D98%分别增加8.7%和11.3%。
核心结论
- 结果表明HIT当前用于CIRT的标准与日本经验高度一致,但为改善肿瘤覆盖可考虑对胃肠道采用更宽松的约束。
- 随着PACK试验进展,预期将对各种临床终点进行进一步分析。
研究设计与样本
- 前瞻性II期PACK研究,分析海德堡离子治疗中心(HIT)14例胰腺癌患者的治疗计划。
- 计划以物理剂量、生物剂量和剂量平均线性能量转移(LETd)重新计算,并使用LEM-I和适配的NIRS-MKM两种模型进行相对生物效应(RBE)加权剂量计算(DBio|HIT和DBio|NIRS)。
主要发现
- 仅2例患者GTV的LETd98%大于44 keV/μm。
- 与原始DBio|HIT相比,DBio|NIRS-const_48Gy和DBio|NIRS-const_50.4Gy使ITV的D98%分别增加8.7%和11.3%。
- NTCP计算显示胃肠道出血概率在DBio|NIRS、DBio|NIRS-const_48Gy和DBio|NIRS-const_50.4Gy分别为4.5%、12.3%和13.0%。
关键数值与推荐
- 基于NIRS经验推导的HIT胃肠道剂量约束为[公式见原文],替代HIT标准Dmax=45.6 GyRBEHIT。
- 再优化方案DBio|NIRS-const_48Gy和DBio|NIRS-const_50.4Gy。
- LETd98%在GTV大于44 keV/μm的患者仅2例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze the dose objectives and constraints applied at the prospective phase II PACK-study at Heidelberg ion therapy center (HIT) for different radiobiological models. METHODS: Treatment plans of 14 patients from the PACK-study were analyzed and recomputed in terms of physical, biological dose and dose-averaged linear energy transfer (LETd). Both LEM-I (local effect model 1) and the adapted NIRS-MKM (microdosimetric kinetic model), were used for relative biological effectiveness (RBE)-weighted dose calculations (DBio|HIT and DBio|NIRS). A new constraint to the gastrointestinal (GI) tract was derived from the National Institute of Radiological Science (NIRS) clinical experience and considered for plan reoptimization (DBio|NIRS-const_48Gy and DBio|NIRS-const_50.4Gy). The Lyman-Kutcher-Burman (LKB) model of Normal Tissue Complication Probability (NTCP) for GI toxicity endpoints was computed. Furthermore, the computed LETd distribution was evaluated and correlated with Local Control (LC). RESULTS: Only two patients showed a LETd98% in the GTV greater than 44 keV/μm. A HIT-dose constraint to the GI of [Formula: see text] was derived from the NIRS experience, in alternative to the standard at HIT Dmax = 45.6 GyRBEHIT. In comparison with the original DBio|HIT,DBio|NIRS-const_48GyandDBio|NIRS-const_50.4Gy resulted in an increase in the ITV's D98% of 8.7% and 11.3%. The NTCP calculation resulted in a probability for gastrointestinal bleeding of 4.5%, 12.3% and 13.0%, for DBio|NIRS, DBio|NIRS-const_48Gy and DBio|NIRS-const_50.4Gy, respectively. CONCLUSION: The results indicate that the current standards applied at HIT for CIRT closely align with the Japanese experience. However, to enhance tumor coverage, a more relaxed constraint on the GI tract may be considered. As the PACK-trial progresses, further analyses of various clinical endpoints are anticipated.
引用
- Baltazar F, Tessonnier T, Haberer T, et al. Carbon-ion radiotherapy (CIRT) as treatment of pancreatic cancer at HIT: initial radiation plan analysis of the prospective phase II PACK-study. Radiother Oncol. 2023. PMID: 37634764. doi:10.1016/j.radonc.2023.109872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。